COMMUNIQUÉS West-GlobeNewswire

Essilor - Communiqué : Des résultats 2017 solides, un très bon 4ème trimestre
01/03/2018
Des résultats 2017 solides Un très bon 4 ème trimestre Version PDF du communiqué Chiffre d'affaires : + 6,7 % hors change et + 3,1 % en base homogène Dynamisme des Etats-Unis et des activités e-commerce Contribution de [...]
News Release: Essilor to allocate exceptional French tax refund to the Group's initiatives to eradicate poor vision
01/03/2018
Essilor to allocate exceptional French tax refund to the Group's initiatives to eradicate poor vision PDF Version of the news release (Charenton-le-Pont - France, March 1 2018) - Essilor today announces that it will [...]
Communiqué : Essilor reverse la totalité du remboursement exceptionnel d'impôt à son combat contre le mal voir
01/03/2018
Essilor reverse la totalité du remboursement exceptionnel d'impôt à son combat contre le mal voir Version PDF du communiqué (Charenton-le-Pont - France, 1 er mars 2018) - Le Groupe Essilor annonce aujourd'hui qu'il [...]
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
01/03/2018
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
REVA to Hold Fourth Quarter and Full Year 2017 Financial Results Call
01/03/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its fourth quarter and full year 2017 financial results and provide a [...]
Agility Health Closes Proposed Transaction with Alliance
01/03/2018
GRAND RAPIDS, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Agility Health, Inc. (TSXV:AHI) (“Agility Health” or the “Company”) announced today that it closed its previously announced transaction with Alliance Physical [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/03/2018
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to [...]
Extendicare Announces 2017 Year End Results
28/02/2018
MARKHAM, Ontario, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) today reported results for the fourth quarter and year ended December 31, 2017. Results are presented in [...]
Galectin Therapeutics to Present at 30th Annual ROTH Conference
28/02/2018
NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s [...]
Retrophin to Present at the Barclays Global Healthcare Conference
28/02/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX ) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday [...]
Intellia Therapeutics to Present at March Healthcare Investor Conferences
28/02/2018
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will [...]
Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
28/02/2018
GAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017 Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017 Filed for Type II variation for uveitis in Europe for ILUVIEN in [...]
TearLab Osmolarity System Launches in Brazil
28/02/2018
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced that it plans to launch the TearLab Osmolarity System at the 2018 Simpósio [...]
Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study
28/02/2018
MENLO PARK, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]
Zomedica Pharmaceuticals Corp. Announces Year End 2017 Financial Results
28/02/2018
ANN ARBOR, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V: ZOM ) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported [...]
Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
28/02/2018
- Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and Improved Motor Function - - Multiple Additional Data Readouts from SCiStar Study Expected in 2018 into First Quarter of 2019 [...]
Clementia Reports 2017 Operating Results and Business Highlights
28/02/2018
Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP) On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter [...]
Clementia annonce ses résultats financiers et faits saillants de 2017
28/02/2018
Recrutement en cours pour l'essai clinique de phase 3 MOVE sur le palovarotene chez les patients atteints de fibrodysplasie ossifiante progressive (FOP) En voie de recruter un premier patient pour l'essai de phase 2 MO- [...]
SeaSpine Announces Fourth Quarter and Full-Year 2017 Results and Issues 2018 Financial Guidance
28/02/2018
CARLSBAD, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]

Pages